Intralesional versus intramuscular methotrexate in the treatment of non-melanoma skin cancers

Résumé

Abstract Background: Intralesional methotrexate (MTX) could be a promising conservative alternative therapy for non-melanoma skin cancers (NMSCs). Systemic MTX was previously attempted as adjuvant for locally-advanced NMSCs. Aim: To compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management. Methods: Sixty patients with histologically-proven NMSCs [keratoacanthoma (KA), basal cell carcinoma (BCC), or squamous cell carcinoma (SCC)], were randomly-assigned into two equal groups: Group A received intralesional MTX injections, and group B was intramuscularly injected with MTX. Injections were repeated weekly until clearance or for 8 sessions. Patients were classified into: responders (>50% improvement), partial responders (<50% improvement), and non-responders to the treatment intervention. Results: In terms of responders, there was a statistically-significant difference in favor of the intralesional MTX group (53.3%) as compared to the intramuscular MTX group (26.7%) (P value=0.04). In groups A and B, respectively, 1-For KA, 88.9% vs 71.4% of patients had a complete resolution; 2-For BCC, 42.8% vs 30% were responders; 3-For SCC, 28.6% vs 0% were responders. Limitations: Low sample size and short follow up. Conclusions: Intralesional MTX is significantly more effective than systemic MTX in the treatment of NMSCs. In KA and lip tumors, both treatment approaches showed excellent response. Trial registration: Registered and approved prospectively by the ethical review board at Faculty of Medicine, Zagazig University.

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0